Literature DB >> 17109467

Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis.

Thomas Bennekov1, Jes Dietrich, Ida Rosenkrands, Anette Stryhn, T Mark Doherty, Peter Andersen.   

Abstract

To analyze the effect of vaccine delivery systems on antigen recognition and vaccine efficacy, we compared immune responses in mice immunized either with an adenovirus vector expressing a fusion of Ag85B and ESAT-6 or with the recombinant fusion protein in a liposomal adjuvant. Both vaccines induced high levels of antigen-specific IFN-gamma production. The adjuvanted protein vaccine induced primarily a CD4 T cell response directed to the epitope Ag85B(241-255) and gave efficient protection against subsequent Mycobacterium tuberculosis infection. In contrast, the adenoviral construct induced a strong CD8 response predominantly targeted to the epitope ESAT-6(15-29) and no significant protection against infection. Vaccination with the protein vaccine resulted in highly accelerated recall of Ag85B(241-255)-specific T cells immediately post M. tuberculosis challenge whereas the ESAT-6(15-29) epitope was barely recognized during infection. Delivery of the viral construct in cationic liposomes switched the immune response to a protective one dominated by CD4 T cells targeted to the Ag85B(241-255) epitope. These data demonstrate that the nature of the T cell response to a vaccine antigen is more important than its magnitude with respect to protective efficacy and that vaccine-mediated changes in immunodominance can result in T cell responses of limited relevance during the natural infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109467     DOI: 10.1002/eji.200636128

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  34 in total

Review 1.  Regulation of CD4 T-cell receptor diversity by vaccine adjuvants.

Authors:  Christina K Baumgartner; Laurent P Malherbe
Journal:  Immunology       Date:  2010-03-17       Impact factor: 7.397

2.  Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection.

Authors:  M Jeyanathan; N Thanthrige-Don; S Afkhami; R Lai; D Damjanovic; A Zganiacz; X Feng; X-D Yao; K L Rosenthal; M Fe Medina; J Gauldie; H C Ertl; Z Xing
Journal:  Mucosal Immunol       Date:  2015-04-15       Impact factor: 7.313

3.  A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults.

Authors:  Thomas J Scriba; Michele Tameris; Erica Smit; Linda van der Merwe; E Jane Hughes; Blessing Kadira; Katya Mauff; Sizulu Moyo; Nathaniel Brittain; Alison Lawrie; Humphrey Mulenga; Marwou de Kock; Lebohang Makhethe; Esme Janse van Rensburg; Sebastian Gelderbloem; Ashley Veldsman; Mark Hatherill; Hendrik Geldenhuys; Adrian V S Hill; Anthony Hawkridge; Gregory D Hussey; Willem A Hanekom; Helen McShane; Hassan Mahomed
Journal:  Am J Respir Crit Care Med       Date:  2012-01-26       Impact factor: 21.405

4.  CBA/J mice generate protective immunity to soluble Ag85 but fail to respond efficiently to Ag85 during natural Mycobacterium tuberculosis infection.

Authors:  Gillian L Beamer; Joshua Cyktor; David K Flaherty; Paul C Stromberg; Bridget Carruthers; Joanne Turner
Journal:  Eur J Immunol       Date:  2012-04       Impact factor: 5.532

5.  Follow-up study of tuberculosis-exposed supermarket customers with negative tuberculin skin test results in association with positive gamma interferon release assay results.

Authors:  Willeke P J Franken; Ben F P J Koster; Ailko W J Bossink; Steven F T Thijsen; John J M Bouwman; Jaap T van Dissel; Sandra M Arend
Journal:  Clin Vaccine Immunol       Date:  2007-07-11

6.  Recombinant adenovirus delivery of calreticulin-ESAT-6 produces an antigen-specific immune response but no protection against a Mycobacterium tuberculosis challenge.

Authors:  S C Esparza-González; A Troy; J Troudt; M J Loera-Arias; J Villatoro-Hernández; E Torres-López; J Ancer-Rodríguez; Y Gutiérrez-Puente; G Muñoz-Maldonado; O Saucedo-Cárdenas; R Montes-de-Oca-Luna; A Izzo
Journal:  Scand J Immunol       Date:  2012-03       Impact factor: 3.487

7.  Adenoviral Type 35 and 26 Vectors with a Bidirectional Expression Cassette in the E1 Region Show an Improved Genetic Stability Profile and Potent Transgene-Specific Immune Response.

Authors:  Marija Vujadinovic; Kerstin Wunderlich; Benoit Callendret; Marina Koning; Mark Vermeulen; Barbara Sanders; Esmeralda van der Helm; Adile Gecgel; Dirk Spek; Karin de Boer; Masha Stalknecht; Jan Serroyen; Maria Grazia Pau; Hanneke Schuitemaker; Roland Zahn; Jerome Custers; Jort Vellinga
Journal:  Hum Gene Ther       Date:  2017-11-30       Impact factor: 5.695

8.  Mycobacterium tuberculosis directs immunofocusing of CD8+ T cell responses despite vaccination.

Authors:  Joshua S Woodworth; Daniel Shin; Mattijs Volman; Cláudio Nunes-Alves; Sarah M Fortune; Samuel M Behar
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

9.  Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response.

Authors:  Benjamin M N Kagina; Brian Abel; Mark Bowmaker; Thomas J Scriba; Sebastian Gelderbloem; Erica Smit; Mzwandile Erasmus; Nonhlanhla Nene; Gerhard Walzl; Gillian Black; Gregory D Hussey; Anneke C Hesseling; Willem A Hanekom
Journal:  Vaccine       Date:  2009-07-17       Impact factor: 3.641

10.  CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.

Authors:  Tara Elvang; Jan P Christensen; Rolf Billeskov; Truc Thi Kim Thanh Hoang; Peter Holst; Allan Randrup Thomsen; Peter Andersen; Jes Dietrich
Journal:  PLoS One       Date:  2009-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.